Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| lung | 12 studies | 27% ± 10% | |
| peripheral blood | 11 studies | 22% ± 3% | |
| kidney | 5 studies | 20% ± 4% | |
| heart | 5 studies | 33% ± 8% | |
| adipose | 5 studies | 36% ± 13% | |
| bone marrow | 3 studies | 26% ± 11% | |
| lymph node | 3 studies | 22% ± 4% | |
| breast | 3 studies | 21% ± 2% | |
| liver | 3 studies | 36% ± 17% | |
| brain | 3 studies | 20% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| intestine | 100% | 19642.94 | 964 / 966 | 98% | 71.67 | 519 / 527 |
| stomach | 98% | 11666.94 | 353 / 359 | 99% | 78.50 | 284 / 286 |
| lung | 100% | 24174.49 | 578 / 578 | 97% | 68.28 | 1116 / 1155 |
| kidney | 100% | 13427.02 | 89 / 89 | 96% | 114.77 | 869 / 901 |
| thymus | 100% | 23058.47 | 652 / 653 | 96% | 58.82 | 581 / 605 |
| breast | 100% | 34347.89 | 459 / 459 | 95% | 57.14 | 1063 / 1118 |
| bladder | 100% | 17198.38 | 21 / 21 | 91% | 48.03 | 459 / 504 |
| prostate | 97% | 10765.15 | 237 / 245 | 90% | 36.10 | 450 / 502 |
| skin | 92% | 18072.63 | 1667 / 1809 | 93% | 67.47 | 440 / 472 |
| adrenal gland | 100% | 12402.06 | 257 / 258 | 81% | 35.78 | 187 / 230 |
| esophagus | 86% | 15229.68 | 1242 / 1445 | 94% | 63.02 | 172 / 183 |
| uterus | 99% | 16786.54 | 169 / 170 | 80% | 30.06 | 365 / 459 |
| pancreas | 77% | 4906.11 | 254 / 328 | 99% | 106.36 | 176 / 178 |
| ovary | 58% | 4706.55 | 105 / 180 | 86% | 29.73 | 371 / 430 |
| liver | 31% | 1731.32 | 71 / 226 | 88% | 35.67 | 356 / 406 |
| adipose | 100% | 39034.65 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 24844.16 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 100% | 15184.63 | 241 / 241 | 0% | 0 | 0 / 0 |
| heart | 98% | 13777.98 | 840 / 861 | 0% | 0 | 0 / 0 |
| brain | 7% | 337.75 | 174 / 2642 | 85% | 27.15 | 596 / 705 |
| lymph node | 0% | 0 | 0 / 0 | 90% | 45.44 | 26 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 76% | 25.50 | 34 / 45 |
| peripheral blood | 55% | 5693.20 | 507 / 929 | 0% | 0 | 0 / 0 |
| muscle | 46% | 2907.59 | 370 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 43% | 7.64 | 34 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0010468 | Biological process | regulation of gene expression |
| GO_1990086 | Biological process | lens fiber cell apoptotic process |
| GO_1990428 | Biological process | miRNA transport |
| GO_0001947 | Biological process | heart looping |
| GO_0003149 | Biological process | membranous septum morphogenesis |
| GO_0002053 | Biological process | positive regulation of mesenchymal cell proliferation |
| GO_0060395 | Biological process | SMAD protein signal transduction |
| GO_0060021 | Biological process | roof of mouth development |
| GO_2000379 | Biological process | positive regulation of reactive oxygen species metabolic process |
| GO_2000563 | Biological process | positive regulation of CD4-positive, alpha-beta T cell proliferation |
| GO_0043011 | Biological process | myeloid dendritic cell differentiation |
| GO_0048701 | Biological process | embryonic cranial skeleton morphogenesis |
| GO_0006468 | Biological process | protein phosphorylation |
| GO_0009410 | Biological process | response to xenobiotic stimulus |
| GO_1905007 | Biological process | positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation |
| GO_0051138 | Biological process | positive regulation of NK T cell differentiation |
| GO_0070723 | Biological process | response to cholesterol |
| GO_0002666 | Biological process | positive regulation of T cell tolerance induction |
| GO_0007224 | Biological process | smoothened signaling pathway |
| GO_0003151 | Biological process | outflow tract morphogenesis |
| GO_0003430 | Biological process | growth plate cartilage chondrocyte growth |
| GO_0007219 | Biological process | Notch signaling pathway |
| GO_0001701 | Biological process | in utero embryonic development |
| GO_0045766 | Biological process | positive regulation of angiogenesis |
| GO_0060391 | Biological process | positive regulation of SMAD protein signal transduction |
| GO_0007369 | Biological process | gastrulation |
| GO_0060463 | Biological process | lung lobe morphogenesis |
| GO_0032147 | Biological process | activation of protein kinase activity |
| GO_1905317 | Biological process | inferior endocardial cushion morphogenesis |
| GO_0060434 | Biological process | bronchus morphogenesis |
| GO_0060412 | Biological process | ventricular septum morphogenesis |
| GO_0001568 | Biological process | blood vessel development |
| GO_0035162 | Biological process | embryonic hemopoiesis |
| GO_0003148 | Biological process | outflow tract septum morphogenesis |
| GO_1905315 | Biological process | cell proliferation involved in endocardial cushion morphogenesis |
| GO_0003181 | Biological process | atrioventricular valve morphogenesis |
| GO_0001570 | Biological process | vasculogenesis |
| GO_0003180 | Biological process | aortic valve morphogenesis |
| GO_0003214 | Biological process | cardiac left ventricle morphogenesis |
| GO_0060443 | Biological process | mammary gland morphogenesis |
| GO_0071363 | Biological process | cellular response to growth factor stimulus |
| GO_0060440 | Biological process | trachea formation |
| GO_0001569 | Biological process | branching involved in blood vessel morphogenesis |
| GO_0007420 | Biological process | brain development |
| GO_0008284 | Biological process | positive regulation of cell population proliferation |
| GO_0003186 | Biological process | tricuspid valve morphogenesis |
| GO_0042127 | Biological process | regulation of cell population proliferation |
| GO_0010634 | Biological process | positive regulation of epithelial cell migration |
| GO_0061520 | Biological process | Langerhans cell differentiation |
| GO_0003274 | Biological process | endocardial cushion fusion |
| GO_0048844 | Biological process | artery morphogenesis |
| GO_0002651 | Biological process | positive regulation of tolerance induction to self antigen |
| GO_0001837 | Biological process | epithelial to mesenchymal transition |
| GO_0032924 | Biological process | activin receptor signaling pathway |
| GO_0007507 | Biological process | heart development |
| GO_2000736 | Biological process | regulation of stem cell differentiation |
| GO_0062009 | Biological process | secondary palate development |
| GO_0002663 | Biological process | positive regulation of B cell tolerance induction |
| GO_1905316 | Biological process | superior endocardial cushion morphogenesis |
| GO_0072091 | Biological process | regulation of stem cell proliferation |
| GO_0035909 | Biological process | aorta morphogenesis |
| GO_0010718 | Biological process | positive regulation of epithelial to mesenchymal transition |
| GO_0002088 | Biological process | lens development in camera-type eye |
| GO_0006915 | Biological process | apoptotic process |
| GO_0007179 | Biological process | transforming growth factor beta receptor signaling pathway |
| GO_0045121 | Cellular component | membrane raft |
| GO_0005576 | Cellular component | extracellular region |
| GO_0009897 | Cellular component | external side of plasma membrane |
| GO_0043235 | Cellular component | receptor complex |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0016020 | Cellular component | membrane |
| GO_0070021 | Cellular component | transforming growth factor beta ligand-receptor complex |
| GO_0005901 | Cellular component | caveola |
| GO_0005829 | Cellular component | cytosol |
| GO_0019209 | Molecular function | kinase activator activity |
| GO_0017002 | Molecular function | activin receptor activity |
| GO_0005524 | Molecular function | ATP binding |
| GO_0060090 | Molecular function | molecular adaptor activity |
| GO_0050431 | Molecular function | transforming growth factor beta binding |
| GO_0004675 | Molecular function | transmembrane receptor protein serine/threonine kinase activity |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0046332 | Molecular function | SMAD binding |
| GO_0048185 | Molecular function | activin binding |
| GO_0005539 | Molecular function | glycosaminoglycan binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0034713 | Molecular function | type I transforming growth factor beta receptor binding |
| GO_0005024 | Molecular function | transforming growth factor beta receptor activity |
| GO_0005026 | Molecular function | transforming growth factor beta receptor activity, type II |
| Gene name | TGFBR2 |
| Protein name | TGF-beta receptor type-2 (EC 2.7.11.30) (TGF-beta type II receptor) (Transforming growth factor-beta receptor type II) receptor protein serine/threonine kinase (EC 2.7.11.30) TGF-beta receptor type-2 (TGFR-2) (EC 2.7.11.30) (TGF-beta type II receptor) (Transforming growth factor-beta receptor type II) (TGF-beta receptor type II) (TbetaR-II) Transforming growth factor, beta receptor II delta TGF-beta receptor type-2 (TGFR-2) (EC 2.7.11.30) (TGF-beta type II receptor) (Transforming growth factor-beta receptor type II) Transforming growth factor, beta receptor II gamma |
| Synonyms | hCG_1997782 |
| Description | FUNCTION: Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. . FUNCTION: Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and thus regulates a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. .; FUNCTION: [Isoform 1]: Has transforming growth factor beta-activated receptor activity. .; FUNCTION: [Isoform 2]: Has transforming growth factor beta-activated receptor activity. .; FUNCTION: [Isoform 3]: Binds TGFB1, TGFB2 and TGFB3 in the picomolar affinity range without the participation of additional receptors. Blocks activation of SMAD2 and SMAD3 by TGFB1. . FUNCTION: Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. . |
| Accessions | A0A8A3P3K3 D2JYI1 W8DY43 A0A0S2Z4H5 A0A0S2Z539 ENST00000295754.10 [P37173-1] W8DYI2 W8DXL6 W8DXU8 P37173 W8DYQ2 ENST00000359013.4 [P37173-2] A3QNQ0 |
